explore -WSS

explore

author：entertainment 2025-10-04 03:59:26 - browse：9698

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Breakthrough Alzheimer’s drugs are inaccessible in rural states

leisure time

WSS

Woodcock on FDA’s accelerated approval and her next chapter

Scientists inch closer to single

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Novo Nordisk to expand supply of Wegovy for U.S. patients

Covid misinformation case heads to Supreme Court

hotspot

explore

focus

New air purifier tech could be key to improving indoor air quality

SAMSHA loosens regulations on methadone treatment centers

As demand for Covid shots wanes, Moderna seeks its next success

Adults seen as increasingly susceptible to measles

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

New air purifier tech could be key to improving indoor air quality

‘Oppenheimer’ and the risks of AI in health care

Heart attack and stroke risk calculators need revising

ARCH Venture Partners is raising $3 billion for a life sciences fund

hotspot

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

New safety details link Apellis eye drug to rare cases of blindness

New safety details link Apellis eye drug to rare cases of blindness

‘Oppenheimer’ and the risks of AI in health care

Vertex non

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

leisure time

leisure time

entertainment

focus